A Phase 4 interventional study of Platelet-rich plasma and Platelet-poor plasma in Nail Diseases, sponsored by Weill Medical College of Cornell University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-23.
Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the efficacy and safety of platelet-rich plasma therapy for brittle nail syndrome
Weill Medical College of Cornell University is the lead sponsor of 892 studies on the registry; 165 are open to participants now.
Of its 123 completed or terminated interventional studies of FDA-regulated products, 94 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Inability of the patient to provide written for any reason.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The proximal nail fold is cleansed with alcohol and platelet-rich plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
Device: Platelet-rich plasma
The proximal nail fold is cleansed with alcohol and platelet-poor plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
Device: Platelet-poor plasma
Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
Physician Global Improvement Assessment (PGIA)
The PGIA will be based on a comparison of photographs taken at baseline to the nails at week 16 of follow-up. The Physician Global Improvement Score (PGIA) evaluates the improvement of lamellar splitting, transverse splitting, ridges, longitudinal grooves, longitudinal splitting, and nail thickness in target fingernails. Change is classified as excellent, good, or fair, or categorized as no improvement or worsening.
Time frame: At 16 weeks
Change From Baseline in Qualify of Life, as Measured by the Modified Nail Psoriasis Quality of Life Scale (NPQ10) Between Baseline and Week 16
The modified NPQ10 comprises 10 questions gauging the impact of brittle nail syndrome on daily activities. Each response is scored from 0 to 2, resulting in a total score between 0 and 20, where higher values indicate a more significant impact. The final scores are converted to percentages, ranging from 0% to 100%, with higher percentages indicating higher functional difficulty experienced. The absolute change in NPQ10 percentage score from baseline to week 16 is reported here.
Time frame: Subjective assessments of quality of life impact due to nail health will be collected at baseline and week 16
Participants were recruited from one location in the United States
| Milestone | Platelet-rich Plasma | Platelet-poor Plasma |
|---|---|---|
| Started | 11 | 11 |
| Completed | 10 | 10 |
| Not completed | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
The PGIA will be based on a comparison of photographs taken at baseline to the nails at week 16 of follow-up. The Physician Global Improvement Score (PGIA) evaluates the improvement of lamellar splitting, transverse splitting, ridges, longitudinal grooves, longitudinal splitting, and nail thickness in target fingernails. Change is classified as excellent, good, or fair, or categorized as no improvement or worsening.
| Fingernails | Platelet-rich Plasma | Platelet-poor Plasma |
|---|---|---|
| Excellent improvement | 5 | 2 |
| Good improvement | 7 | 1 |
| Fair improvement | 9 | 2 |
| No improvement | 42 | 13 |
| Worse | 10 | 2 |
The modified NPQ10 comprises 10 questions gauging the impact of brittle nail syndrome on daily activities. Each response is scored from 0 to 2, resulting in a total score between 0 and 20, where higher values indicate a more significant impact. The final scores are converted to percentages, ranging from 0% to 100%, with higher percentages indicating higher functional difficulty experienced. The absolute change in NPQ10 percentage score from baseline to week 16 is reported here.
| percentage | All Groups |
|---|---|
| Change From Baseline in Qualify of Life, as Measured by the Modified Nail Psoriasis Quality of Life Scale (NPQ10) Between Baseline and Week 16 | 10 (0 to 60) |
Collected over 16 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Platelet-rich Plasma | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Platelet-poor Plasma | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Event | Platelet-rich Plasma | Platelet-poor Plasma |
|---|---|---|
| Subungual hematomaSkin and subcutaneous tissue disorders | 3/10 | 2/10 |
| OnychomadesisSkin and subcutaneous tissue disorders | 2/10 | 2/10 |
| LeukonychiaSkin and subcutaneous tissue disorders | 1/10 | 0/10 |
| Beau's line(s)Skin and subcutaneous tissue disorders | 1/10 | 0/10 |
| Age, Continuous(years) | Platelet-rich Plasma | Platelet-poor Plasma | Total |
|---|---|---|---|
| Mean | 67.8 ± 6 | 67.8 ± 6 | 67.8 ± 6 |
| Sex/Gender, Customized(participants) | Platelet-rich Plasma | Platelet-poor Plasma | Total |
|---|---|---|---|
| Female | 10 | 10 | 10 |
| Male | 1 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | Platelet-rich Plasma | Platelet-poor Plasma | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 10 | 10 | 10 |
| More than one race | 0 | 0 | 0 |
| Unknown Race or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Platelet-rich Plasma | Platelet-poor Plasma | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 2 |
| Not Hispanic or Latino | 9 | 9 | 9 |
| Unknown Ethnicity or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Platelet-rich Plasma | Platelet-poor Plasma | Total |
|---|---|---|---|
| United States | 11 | 11 | 11 |
| Physician Global Assessment (PGA)(score on a scale) | Platelet-rich Plasma | Platelet-poor Plasma | Total |
|---|---|---|---|
| Mean | 3.16 (0 to 12) | 2.7 (0 to 10) | 3.06 (0 to 12) |
| Nail Superficial Abnormality Index (NSAI)(score on a scale) | Platelet-rich Plasma | Platelet-poor Plasma | Total |
|---|---|---|---|
| Mean | 3.5 (0 to 8) | 3.4 (0 to 8) | 3.5 (0 to 8) |
| Modified Nail Psoriasis Quality of Life Scale (NPQ10)(Percentage) | Platelet-rich Plasma | Platelet-poor Plasma | Total |
|---|---|---|---|
| Mean | 16.5 (0 to 75) | 16.5 (0 to 75) | 16.5 (0 to 75) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification.
Supporting information: Study protocol
Time frame: Immediately following publication.
Access criteria: Anyone who wishes to access the data.
Ran from Mar 2021 to primary completion in Apr 2023, 25 months.
Results were first posted in Apr 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nail Diseases
Weill Medical College of Cornell University →